Immunogenicity of an electron beam inactivated Rhodococcus equi vaccine in neonatal foals

PLoS One. 2014 Aug 25;9(8):e105367. doi: 10.1371/journal.pone.0105367. eCollection 2014.

Abstract

Rhodococcus equi is an important pathogen of foals that causes severe pneumonia. To date, there is no licensed vaccine effective against R. equi pneumonia of foals. The objectives of our study were to develop an electron beam (eBeam) inactivated vaccine against R. equi and evaluate its immunogenicity. A dose of eBeam irradiation that inactivated replication of R. equi while maintaining outer cell wall integrity was identified. Enteral administration of eBeam inactivated R. equi increased interferon-γ production by peripheral blood mononuclear cells in response to stimulation with virulent R. equi and generated naso-pharyngeal R. equi-specific IgA in newborn foals. Our results indicate that eBeam irradiated R. equi administered enterally produce cell-mediated and upper respiratory mucosal immune responses, in the face of passively transferred maternal antibodies, similar to those produced in response to enteral administration of live organisms (a strategy which previously has been documented to protect foals against intrabronchial infection with virulent R. equi). No evidence of adverse effects was noted among vaccinated foals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actinomycetales Infections / prevention & control
  • Actinomycetales Infections / veterinary*
  • Animals
  • Bacterial Vaccines / therapeutic use*
  • Horse Diseases / immunology*
  • Horses / immunology*
  • Immunity, Active*
  • Rhodococcus equi / immunology
  • Rhodococcus equi / ultrastructure

Substances

  • Bacterial Vaccines

Grants and funding

This work was supported by the Morris Animal Foundation (D13EQ-0001). Additional funding was provided by the Link Equine Research Endowment, Texas A&M University. AIB was supported by a fellowship from Fort Dodge Animal Health/Pfizer Animal Health (now Zoetis). An unrestricted gift from Boehringer-Ingelheim to the Equine Infectious Disease Laboratory at Texas A&M University provided partial support to this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.